Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.


Treatment with the chimeric anti-CD20 monoclonal antibody rituximab induces rapid and long-lasting depletion of circulating B cells. We report the occurrence of enteroviral meningoencephalitis following rituximab therapy in 1 child with immune thrombocytopenia and in 1 adult patient with relapsed B cell lymphoma.

Citations per Year

837 Citations

Semantic Scholar estimates that this publication has 837 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Quartier2003EnteroviralMA, title={Enteroviral meningoencephalitis after anti-CD20 (rituximab) treatment.}, author={Pierre Quartier and Olivier Tournilhac and Christine Archimbaud and Leila Lazaro and Carine Chaleteix and Pascale Millet and H{\'e}l{\`e}ne Peigue-Lafeuille and S. Buffet Croix Blanche and Alain Fischer and Jean-Laurent Casanova and Philippe Travade and Marc Tardieu}, journal={Clinical infectious diseases : an official publication of the Infectious Diseases Society of America}, year={2003}, volume={36 3}, pages={e47-9} }